Hey Song Corporation (TPE:1234)

Oncternal Therapeutics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	10,030	10,251	10,576	9,558	9,223	9,205
Revenue Growth (YoY)	-5.85%	-3.07%	10.65%	3.64%	0.19%	0.65%
Cost of Revenue	7,111	7,205	7,611	6,880	6,662	6,570
Gross Profit	2,919	3,046	2,966	2,679	2,561	2,635
Selling, General & Admin	2,487	2,429	2,324	2,164	1,903	1,964
Research & Development	62.3	59.24	57.51	55.73	52.05	56.59
Operating Expenses	2,549	2,488	2,381	2,218	1,955	2,020
Operating Income	370.14	558.13	584.56	460.83	605.94	615.54
Interest Expense	-31.45	-23.95	-16.23	-13.76	-8.79	-12.7
Interest & Investment Income	18.59	17.78	14.45	7.11	7.02	6.8
Earnings From Equity Investments	-3.88	9.59	4.49	14.21	-23.12	36.64
Currency Exchange Gain (Loss)	8.67	8.67	3.37	31.18	-6.78	-33.49
Other Non Operating Income (Expenses)	758.94	616.41	601.58	591.77	425.76	421.33
EBT Excluding Unusual Items	1,121	1,187	1,192	1,091	1,000	1,034
Gain (Loss) on Sale of Investments	4.21	4.21	3.52	1.08	0.55	0.49
Gain (Loss) on Sale of Assets	1.64	1.64	0.82	1.77	0.54	0.49
Pretax Income	1,127	1,192	1,197	1,094	1,001	1,035
Income Tax Expense	218.1	245.1	248.11	208.03	204.31	144.93
Net Income	908.77	947.4	948.45	886.14	796.81	890.16
Net Income to Common	908.77	947.4	948.45	886.14	796.81	890.16
Net Income Growth	-7.17%	-0.11%	7.03%	11.21%	-10.49%	5.16%
Shares Outstanding (Basic)	403	402	402	402	402	402
Shares Outstanding (Diluted)	403	402	402	402	402	402
Shares Change (YoY)	0.19%	-0.00%	-0.01%	0.01%	-0.01%	0.01%
EPS (Basic)	2.26	2.36	2.36	2.21	1.98	2.22
EPS (Diluted)	2.26	2.36	2.36	2.20	1.98	2.21
EPS Growth	-7.34%	-0.11%	7.27%	11.11%	-10.41%	5.24%
Free Cash Flow	239.26	70.13	1,041	600.18	877.45	1,245
Free Cash Flow Per Share	0.59	0.17	2.59	1.49	2.18	3.09
Dividend Per Share	-	1.900	1.900	1.800	1.700	1.800
Dividend Growth	-	-	5.56%	5.88%	-5.56%	5.88%
Gross Margin	29.10%	29.72%	28.04%	28.03%	27.77%	28.63%
Operating Margin	3.69%	5.44%	5.53%	4.82%	6.57%	6.69%
Profit Margin	9.06%	9.24%	8.97%	9.27%	8.64%	9.67%
Free Cash Flow Margin	2.39%	0.68%	9.84%	6.28%	9.51%	13.52%
EBITDA	689.56	878.6	909.2	787.43	934.72	942.84
EBITDA Margin	6.88%	8.57%	8.60%	8.24%	10.13%	10.24%
D&A For EBITDA	319.42	320.47	324.63	326.6	328.78	327.3
EBIT	370.14	558.13	584.56	460.83	605.94	615.54
EBIT Margin	3.69%	5.44%	5.53%	4.82%	6.57%	6.69%
Effective Tax Rate	19.35%	20.55%	20.73%	19.01%	20.41%	14.00%
Revenue as Reported	10,030	10,251	10,576	9,558	9,223	9,205

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.